Latest Ratios: P/E Ratio -15.7x · EV/EBITDA N/A · ROE -17.5%. (2002–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $540M | $418M | $254M | $373M | $766M | $886M | $388M | $704M | $789M | $557M | $434M |
| Enterprise Value | $494M | $372M | $182M | $393M | $771M | $858M | $374M | $613M | $809M | $616M | $535M |
| P/E Ratio → | -15.75 | — | — | — | — | — | — | 11.46 | 47.80 | 79.37 | — |
| P/S Ratio | 1.85 | 1.43 | 0.83 | 1.10 | 2.42 | 3.05 | 1.47 | 1.96 | 2.29 | 1.59 | 1.23 |
| P/B Ratio | 2.93 | 2.28 | 1.23 | 0.99 | 1.80 | 2.02 | 0.85 | 1.15 | 1.45 | 1.08 | 0.86 |
| P/FCF | — | — | — | — | — | 46.89 | — | 20.52 | 20.98 | 10.57 | 10.96 |
| P/OCF | — | — | — | 4788.26 | — | 36.79 | — | 18.81 | 19.12 | 10.00 | 9.60 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.27 | 0.60 | 1.16 | 2.44 | 2.95 | 1.42 | 1.71 | 2.35 | 1.76 | 1.51 |
| EV / EBITDA | — | — | — | — | 877.81 | — | — | 37.20 | 89.97 | 45.16 | 18.38 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 4056.22 |
| EV / FCF | — | — | — | — | — | 45.40 | — | 17.87 | 21.50 | 11.67 | 13.51 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.9% | 53.9% | 50.9% | 51.4% | 52.4% | 53.9% | 56.9% | 43.4% | 41.8% | 41.2% | 49.3% |
| Operating Margin | -13.7% | -13.7% | -63.3% | -15.1% | -9.0% | -12.1% | -63.3% | -2.6% | -4.1% | -3.2% | 0.3% |
| Net Profit Margin | -11.6% | -11.6% | -60.7% | -15.5% | -8.4% | -10.8% | -63.1% | 17.1% | 4.7% | -2.0% | -12.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -17.5% | -17.5% | -63.1% | -13.1% | -6.1% | -7.0% | -31.2% | 10.6% | 3.1% | -1.4% | -8.3% |
| ROA | -11.4% | -11.4% | -43.4% | -9.7% | -4.8% | -5.5% | -23.3% | 8.0% | 2.3% | -1.0% | -5.8% |
| ROIC | -22.1% | -22.1% | -54.2% | -9.3% | -5.1% | -6.2% | -25.9% | -1.3% | -1.9% | -1.4% | 0.1% |
| ROCE | -18.6% | -18.6% | -57.0% | -11.0% | -5.8% | -6.7% | -25.6% | -1.3% | -2.2% | -1.7% | 0.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.02 | 0.17 | 0.08 | 0.05 | 0.09 | 0.22 | 0.17 | 0.20 | 0.26 |
| Debt / EBITDA | — | — | — | — | 38.48 | — | — | 8.28 | 10.42 | 7.77 | 4.58 |
| Net Debt / Equity | — | -0.25 | -0.35 | 0.05 | 0.01 | -0.06 | -0.03 | -0.15 | 0.04 | 0.11 | 0.20 |
| Net Debt / EBITDA | — | — | — | — | 5.65 | — | — | -5.53 | 2.18 | 4.28 | 3.47 |
| Debt / FCF | — | — | — | — | — | -1.49 | — | -2.65 | 0.52 | 1.11 | 2.55 |
| Interest Coverage | — | — | — | -6.91 | -26.48 | -40.87 | -184.37 | -1.88 | -4.64 | -4.04 | 0.04 |
Net cash position: cash ($56M) exceeds total debt ($10M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.21 | 2.21 | 2.12 | 1.95 | 1.93 | 2.45 | 2.97 | 4.30 | 2.93 | 2.21 | 2.18 |
| Quick Ratio | 1.40 | 1.40 | 1.46 | 1.29 | 1.24 | 1.60 | 1.80 | 3.75 | 2.25 | 1.43 | 1.35 |
| Cash Ratio | 0.73 | 0.73 | 0.83 | 0.53 | 0.39 | 0.84 | 1.06 | 3.11 | 1.32 | 0.70 | 0.51 |
| Asset Turnover | — | 1.04 | 0.96 | 0.64 | 0.57 | 0.52 | 0.44 | 0.43 | 0.49 | 0.49 | 0.49 |
| Inventory Turnover | 2.17 | 2.17 | 2.46 | 2.97 | 2.93 | 2.76 | 1.90 | 2.86 | 3.00 | 2.31 | 3.24 |
| Days Sales Outstanding | — | 53.83 | 60.06 | 56.92 | 65.21 | 46.80 | 47.22 | 44.25 | 41.77 | 48.40 | 54.56 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 8.7% | 2.1% | 1.3% | — |
| FCF Yield | — | — | — | — | — | 2.1% | — | 4.9% | 4.8% | 9.5% | 9.1% |
| Buyback Yield | 0.3% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 0.0% |
| Total Shareholder Yield | 0.3% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 0.0% |
| Shares Outstanding | — | $41M | $40M | $39M | $39M | $38M | $38M | $37M | $38M | $37M | $36M |
Persistent Operating Losses
According to current market data, ANGO trades at a price-to-sales multiple of 1.89, which suggests that investors are pricing the company as a distressed asset rather than a high-growth medical technology innovator, especially when compared to the premium multiples typically assigned to specialized oncology-focused peers like Penumbra.
The absence of a meaningful forward P/E ratio underscores the market's skepticism regarding the company's near-term path to GAAP profitability. This valuation discount appears to reflect a lack of confidence in the current revenue trajectory, as the market waits for tangible evidence that the NanoKnife platform can scale sufficiently to offset the loss of legacy revenue streams.
Based on reported financial statements, ANGO's ROIC has remained consistently negative over the last ten quarters, bottoming out at -61.3% in 2024Q3, which indicates that the company is currently destroying shareholder value rather than compounding it through its ongoing investments in specialized medical technology and clinical trials.
The persistent negative returns on invested capital suggest that the company's current cost structure is fundamentally misaligned with its revenue-generating capacity. Investors should monitor whether the recent divestiture of lower-margin business lines can eventually drive a pivot toward positive capital returns, though current trends show no such inflection.
As reported in recent filings, ANGO's cash conversion cycle remains elevated at 124 days in 2026Q3, driven largely by a high days-inventory-outstanding metric of 151 days, which suggests that the company faces significant challenges in managing its supply chain and inventory turnover for specialized medical instruments.
The high DIO relative to industry standards implies that the company may be carrying excess inventory of legacy products or struggling with the production ramp-up of newer technologies. This inefficiency ties up critical liquidity and warrants further investigation into whether the company's inventory management processes are optimized for its new, leaner operational focus.
Based on the most recent quarterly data, ANGO maintains a current ratio of 2.35, which provides a superficial sense of stability; however, this liquidity position is increasingly reliant on the company's remaining asset base rather than consistent cash generation from its core oncology and endovascular product lines.
While the current ratio appears healthy, the company's persistent operating losses suggest that this liquidity buffer is being slowly eroded by ongoing cash burn. Investors should monitor the company's ability to maintain this ratio without resorting to dilutive financing, as the current cash flow profile remains highly volatile and dependent on working capital management.
The price-to-sales ratio is frequently misapplied to ANGO, as it obscures the company's ongoing transition from a broad-based medical device supplier to a niche oncology player, failing to account for the significant margin profile differences between legacy vascular access products and the high-margin NanoKnife disposable revenue stream.
Using P/S as a primary valuation metric ignores the quality of revenue, which is the most critical factor for this business model. A more appropriate approach would involve evaluating the company based on the 'probe-to-console' utilization ratio and the potential for high-margin recurring revenue growth, which are the true drivers of long-term value.
Includes 30+ ratios · 24 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ANGO stock.
AngioDynamics, Inc.'s current P/E ratio is -15.7x. The historical average is 53.6x.
AngioDynamics, Inc.'s return on equity (ROE) is -17.5%. The historical average is 4.6%.
Based on historical data, AngioDynamics, Inc. is trading at a P/E of -15.7x. Compare with industry peers and growth rates for a complete picture.
AngioDynamics, Inc. has 53.9% gross margin and -13.7% operating margin.